- Financial Times•2 days ago
To most people who have encountered Emma Walmsley, her appointment this week as the next head of GlaxoSmithKline, the UK drugmaker, will probably come as little surprise. "She's ruthlessly ambitious," ...
- Reuters•2 days ago
Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building. A few years ago, the developing world was seen as a savior as patent after patent expired across the United States and Europe, but emerging market sales growth at the top drug firms slowed to less than two percent in the latest quarter. Forecasts from independent experts IMS Health now suggest the United States will account for 55 percent of sales growth between 2016 and 2020, with emerging markets only contributing 30 percent.
GlaxoSmithKline plc (GSK)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||42.90 x 200|
|Ask||43.65 x 200|
|Day's Range||43.18 - 43.53|
|52wk Range||37.24 - 45.58|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||2,713.75|
|Avg Vol (3m)||3,084,321|
|Dividend & Yield||2.20 (5.06%)|